Gene · 53345
Papers1,658
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
141 to 160 of 1,658
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Deciphering the shared genetic architecture between bipolar disorder and body mass index. | J Affect Disord | 2025 | 40056998 | PubTator, text mining | PubMed |
| Exploring the impact of graded alcohol use on atherogenic lipid profiles among Latinos with underlying chronic liver disease. | Alcohol Clin Exp Res (Hoboken) | 2025 | 40022301 | PubTator, text mining | PubMed |
| Diagnostic Performance of Serum Mac-2-Binding Protein Glycosylation Isomer as a Fibrosis Biomarker in Non-Obese and Obese Patients with MASLD. | Biomedicines | 2025 | 40002828 | PubTator, text mining | PubMed |
| Prevalence and Clinical Correlation of Cardiometabolic Risk Factors in Alcohol-Related Liver Disease and Metabolic Dysfunction and Alcohol Associated Liver Disease (MetALD). | J Clin Exp Hepatol | 2025 | 39926026 | PubTator, text mining | PubMed |
| Author Correction: Intestinal TM6SF2 protects against metabolic dysfunction-associated steatohepatitis through the gut-liver axis. | Nat Metab | 2025 | 39838065 | PubTator, text mining | PubMed |
| Genetic risk amplifies lifestyle effects on hepatic steatosis and its progression: Insights from a population-based cohort. | Dig Liver Dis | 2025 | 39837741 | PubTator, text mining | PubMed |
| TM6SF2 as new intestinal lipid player. | Nat Metab | 2025 | 39794538 | PubTator, text mining | PubMed |
| Intestinal TM6SF2 protects against metabolic dysfunction-associated steatohepatitis through the gut-liver axis. | Nat Metab | 2025 | 39779889 | PubTator, text mining | PubMed |
| Genetic Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease. | Gut Liver | 2025 | 39774124 | PubTator, text mining | PubMed |
| Dissecting the shared genetic architecture between nonalcoholic fatty liver disease and type 2 diabetes. | Hum Mol Genet | 2025 | 39690818 | PubTator, text mining | PubMed |
| Deep metabolic phenotyping of humans with protein-altering variants in TM6SF2 using a genome-first approach. | JHEP Rep | 2025 | 39687601 | PubTator, text mining | PubMed |
| Type 2 diabetes and the minor allele of PNPLA3 consistently identify high-risk metabolic dysfunction associated steatotic liver disease. | Diabetes Res Clin Pract | 2025 | 39675485 | PubTator, text mining | PubMed |
| Hepatic TM6SF2 activates antitumour immunity to suppress metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma and boosts immunotherapy. | Gut | 2025 | 39667906 | PubTator, text mining | PubMed |
| Metabolomics profiling in multi-ancestral individuals with type 2 diabetes in Singapore identified metabolites associated with renal function decline. | Diabetologia | 2025 | 39621102 | PubTator, text mining | PubMed |
| Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations. | Clin Mol Hepatol | 2025 | 39439408 | PubTator, text mining | PubMed |
| Clinical Utility of Genetic Variants in PNPLA3 and TM6SF2 to Predict Liver-Related Events in Metabolic Dysfunction-Associated Steatotic Liver Disease. | Liver Int | 2025 | 39373247 | PubTator, text mining | PubMed |
PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on "TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD". | Clin Mol Hepatol | 2025 | 39253745 | PubTator, text mining | PubMed |
| TM6SF2 and PNPLA3: A potential dynamic duo?: Editorial on "TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD". | Clin Mol Hepatol | 2025 | 39188231 | PubTator, text mining | PubMed |
| Contribution of Sex Differences to the Development of Cardiovascular Disease in Metabolic-Associated Steatotic Liver Disease (MASLD). | Int J Transl Med (Basel) | 2024 | 40988882 | PubTator, text mining | PubMed |
| Transcriptome-Wide Association Study of Metabolic Dysfunction-Associated Steatotic Liver Disease Identifies Relevant Gene Signatures. | Turk J Gastroenterol | 2024 | 39763192 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/53345/papers?page=8